RecruitingNCT07029373

Plasma Calcitonin Gene-Related Peptide (CGRP) Levels in Patients With Head and Neck Malignancies Undergoing Radiotherapy

A Prospective Clinical Study for Analyzing Plasma Calcitonin Gene-Related Peptide (CGRP) Levels in Patients With Head and Neck Malignancies Undergoing Radiotherapy


Sponsor

West China Hospital

Enrollment

50 participants

Start Date

Jul 4, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This prospective study investigates the dynamic changes in plasma calcitonin gene-related peptide (CGRP) levels during radiotherapy and their association with radiotherapy-related pain in patients with head and neck malignancies.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Age ≥ 18 years
  • Histologically confirmed head and neck malignancy
  • Planned to receive definitive or postoperative adjuvant radiotherapy
  • Radiotherapy duration ≥ 4 weeks, with irradiation field involving the oral cavity, pharynx, or neck region
  • Able and willing to provide written informed consent
  • Able to complete pain assessments and blood sample collection

Exclusion Criteria6

  • History of significant chronic pain prior to radiotherapy (e.g., postherpetic neuralgia, rheumatoid arthritis)
  • Presence of uncontrolled hypertension, diabetes, or migraines
  • Presence of other active malignancies or major systemic diseases (e.g., severe hepatic or renal dysfunction)
  • Currently receiving or recently received treatments that may significantly affect pain perception (e.g., opioids, antidepressants)
  • Pregnant or breastfeeding
  • Inability to complete follow-up or poor treatment compliance

Locations(1)

West China Hospital, Sichuan University

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07029373


Related Trials